Catherine Shannon - Concepedia

Author

Catherine Shannon

Also Known As

C M Shannon, C. Shannon, C.M. Shannon, Catherine M Shannon, Catherine M. Shannon, Catherine Shannon, Shannon, Catherine, Sumitra Ananda

100

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Mater Health Services Mater Research The University of Queensland Mater Adult Hospital Peter MacCallum Cancer Centre

About

Catherine Shannon is an author at Mater Health Services specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	668
2	Health Sciences	1	1	39
3	Public Health	1	1	18
4	Cell Biology	1	1	39
5	Cellular Physiology	1	1	39

Catherine Shannon

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals Alistair Ring, Ian E. Smith, Alison Jones, Journal of Clinical Oncology	2005	276
Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status Michael Glantz, Walter A. Hall, Bernard F. Cole, Cancer	1995	192
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial Yoland Antill, Peey‐Sei Kok, Kristy Robledo, Journal for ImmunoTherapy of Cancer	2021	120
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen, Clinical Cancer Research	2022	86
Does Timing of Adjuvant Chemotherapy for Early Breast Cancer Influence Survival? Catherine Shannon, S. Ashley, Ian E. Smith Journal of Clinical Oncology	2003	85
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer Brittney S. Harrington, Yaowu He, Claire M. Davies, British Journal of Cancer	2016	80
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance Yaowu He, Andy Wu, Brittney S. Harrington, Oncogene	2015	71
Human Toxic Neutrophils. III. Metabolic Characteristics Charles E. McCall, Lawrence R. DeChatelet, Michael R. Cooper, The Journal of Infectious Diseases InflammationOxygen UtilizationNitrosative StressMedicineGranulocyte	1973	56
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). Yoland Antill, Peey‐Sei Kok, Kristy Robledo, Journal of Clinical Oncology Tumor BiologyLymphoid NeoplasiaMedicineImmunologyGynecology	2019	55

Page 1